Medical Practice Guidelines for Lung Cancers including malignant pleural mesotheliomas and thymic tumors according to evidence-based medicine. 2024. Edited by the Japan Lung Cancer Society. Chapter 3 Guidelines for thymic epithelial tumors - Summary of recommendations

Japanese clinical guidelines for thymic epithelial tumors were initially presented by the Guidelines Committee of the Japan Lung Cancer Society (JLCS) in 2016. They are comprised of a set of evidence-based recommendations regarding clinical diagnosis, as well as treatment and pathological diagnosis of thymoma, thymic carcinoma, and thymic neuroendocrine tumor cases. Treatment recommendations are dependent on tumor stage and recurrence status, while treatment modalities include surgery, radiation therapy, chemotherapy, and multimodality therapy. Additionally, recommendations cover methods for handling resected specimens and consideration of essential contents for determining pathological diagnosis. Since the first version of the guidelines, there have been significant improvements in treatment options, including molecular target therapy, immune checkpoint inhibitor administration, and robotic surgery. In addition, a novel staging system using TNM classification of thymic epithelial tumor was established and approved by the Union of International Cancer Control in 2017. The JLCS performs annual reviews of the clinical guidelines for updating associated data and publishes a revised version biennially. The present report summarizes the most recent recommendations for treatment of thymic epithelial tumors, published in 2024.

Published by Respiratory investigation, 2025. The guideline itself is at the source linked here.

doi.org/10.1016/j.resinv.2025.09.005